|Bid||9.78 x 1400|
|Ask||9.83 x 1100|
|Day's Range||9.74 - 9.88|
|52 Week Range||6.55 - 15.98|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 13, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.25|
Urovant Sciences Appoints James Hindman to Board of Directors
Urovant Sciences to Present at the Jefferies Virtual Healthcare Conference
Urovant Sciences (Nasdaq: UROV) announced today that data from the vibegron EMPOWUR 52-week extension study (NCT03583372) and data by age groups from the 12-week placebo-controlled EMPOWUR study (NCT03492281) will be presented virtually by the authors during the 2020 American Urological Association (AUA) Annual Meeting and will be available for viewing on the annual meeting website, on May 15, 2020.
Urovant Sciences (Nasdaq: UROV) today announced the appointment of accomplished industry veteran Jim Robinson to the position of President and Chief Executive Officer. Mr. Robinson will continue his service as a member of the Urovant Board of Directors. Mr. Robinson is succeeding Urovant’s founding CEO Keith Katkin, who will transition to the role of advisor to the Urovant Board for the next five years.
Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder
Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 31.) Aptose Biosciences Inc (NASDAQ: APTO ) ...
Urovant Sciences Ltd (NASDAQ: UROV) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval of once-daily, 75mg vibegron for the treatment of patients with an overactive bladder. "Our NDA submission for vibegron is a significant milestone for our company and brings us one step closer to potentially providing a new oral therapy to a highly dissatisfied market," said Keith Katkin, CEO of Urovant in a statement.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...
NEW YORK, NY / ACCESSWIRE / June 13, 2019 / Urovant Sciences Ltd. (NASDAQ: UROV ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on June 13, 2019 at 4:30 PM ...